ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

insulin glulisine

Also written as “Insulin Glulisine”, “Insulin glulisine” and “INSULIN GLULISINE”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 4 companies.

Drug pageInsulin glulisine: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 3, 200642 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only380 open or runningphase 4since Aug 3, 2006Sep 20, 2002none ahead
ikfe-CRO20 open or runningphase 4since Aug 15, 2011Aug 15, 2011none ahead
Geropharmits history only10 open or runningphase 3since Jul 9, 2025Jul 9, 2025none ahead
Profil Institut für Stoffwechselforschungits history only10 open or runningphase 1since Aug 31, 2009Aug 31, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ikfe-CRO only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2011First study: phase 4 study in Diabetes Mellitus, Type 2First studyNCT01417897 · 12 enrolled · Germany
  2. Dec 5, 2011Phase 4 study in Diabetes Mellitus, Type 2NCT01500850 · 60 enrolled · Germany

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

All 2 ikfe-CRO leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01500850Diabetes Mellitus, Type 2 · Germany4UNKNOWNOct 201260
NCT01417897Diabetes Mellitus, Type 2 · Germany4UNKNOWNMay 201212

How it is read

Names in the registry

  • “Insulin Glulisine”, 12 entries
  • “Insulin glulisine”, 11 entries
  • “insulin glulisine”, 8 entries
  • “INSULIN GLULISINE”, 4 entries
  • “INSULIN GLULISINE (HMR1964)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.